OncoHost is advancing a new paradigm in precision oncology.
The PROphet® platform supports clinical decision-making by identifying plasma proteomic
patterns associated with resistance to therapy, predicting response to treatment,
and enabling earlier biology-driven interventions to optimize clinical outcomes.
The PROphet® platform supports clinical decision-making by identifying plasma proteomic
patterns associated with resistance to therapy, predicting response to treatment,
and enabling earlier biology-driven interventions to optimize clinical outcomes.
Plasma Proteomic Profiling
Analyzing the biological interplay of the patient, tumor, and therapy can:
Enable early prediction
of individual response
to immunotherapy
of individual response
to immunotherapy
Identify relevant therapeutic
strategies that may overcome
potential resistance to therapy
strategies that may overcome
potential resistance to therapy
A new approach to
managing therapeutic strategies
Blood-based test
Not exclusive to
mutation carriers
mutation carriers
Response
probability report
probability report
Stratification of next-line treatment
options
options
Combination
therapy analysis
therapy analysis